Clinical Trial Update: Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating polymer-lipid particle-delivered CAR1920 mRNA CAR-T therapy for relapsed/refractory B-cell lymphoma and leukemia is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Leukemia

Drugs mentioned

• CAR1920 mRNA CAR-T Therapy

Snippet

Sponsor: Daihong Liu | Conditions: B-cell Lymphoma Refractory | Phase 2 | Status: RECRUITING